Emerging clinical drug development company Emyria (ASX:EMD) has announced the appointment of experienced drug development executive Dr Karen Smith to its board.
“We’re delighted to appoint Dr Karen Smith to our Board," said managing director Dr Michael Winlo. "Dr Smith is a highly acclaimed and respected pharmaceutical executive, who has overseen multiple successful drug registrations and has already been advising Emyria since February as Chair of our Strategic Advisory.
"Dr Smith has held key Chief Executive Officer and Chief Medical Officer roles at some of the most innovative Biotech and Pharmaceutical development companies in the world including the role of Chief Medical Officer and Global Head of Research and Development at Jazz Pharmaceuticals.
Dr Winlo continued, "We believe Dr Smith's extensive experience, professional network and track record of successful drug registrations in biopharma will greatly benefit Emyria’s multiple drug registration programs.”
Dr Smith has overseen more than 100 clinical trials and more than 20 regulatory approvals leading to product launches across diverse therapeutic areas including neuroscience, rare disease, oncology, cardiology, dermatology, oncology and anti-infectives.
Dr Smith's experience in business development includes the acquisition of US and international companies, divestitures and negotiating partnership deals.
Dr Smith was also the founding CEO of the Minderoo Foundation’s Eliminate Cancer Initiative supported by Andrew Forrest and remains an advisor to that program.
“Emyria is uniquely placed to accelerate treatment development as one of only a few companies operating a network of clinical services, curating proprietary Real-World Evidence and developing novel treatments. I look forward to assisting the team make progress on its global pharmaceutical development and registration goals,” said Dr Smith.